pro medicus investor centre
Domain Group offers an ecosystem of leading multi-platform property solutions. Half Year Results. Investor Presentation FY2019. Find out more Find out more about our businesses and brands Last updated: 1:06PM 04/03/2021 AEST | Minimum 30 minutes delay. Add Files. So the EPS growth rate is rather close to the annualized share price gain of 55% per year. Five institutional investors are understood to have participated in the company’s heavily oversubscribed capital raising alongside sophisticated and retail investors. Alternatively, shareholders may contact Computershare as follows: Mail. Radiology software stock Pro Medicus (ASX:PME) was once a small cap trading for only around 50c a share. HIN/SRN ASX Release 1H2020. Half year results announcement: 25/02/2021: Preliminary Final Results announcement: 26/08/2021: Annual General Meeting: 05/11/2021 Postcode or Outside Aus tralia. View our 2017 Annual Report here. The company has offices in Richmond, Victoria, Berlin, Germany and in the United States. On a statutory basis, Pro Medicus' revenue was up 15.7 per cent on the previous corresponding period, but this included a one-off gain of $3.05 million from a … Pro Medicus Limited A final option to consider is Pro Medicus. PRO MEDICUS LIMITED . PRO MEDICUS LIMITED . ASX Release FY2019. Add … Pinnacle is committed to good corporate governance. Add Files. Chairman from 2003 to 2007. Company Overview. Full Year Results. The company provides a comprehensive range of health imaging software and services to hospitals, imaging centres, and health care groups worldwide. Jaz … Over half a decade, Pro Medicus managed to grow its earnings per share at 47% a year. Pro Medicus Ltd 1.84% Sectors Sectors; Sectors Weight; Technology 38.12% ... is a solution powered by Digital Look Ltd incorporating their prices, data, news, charts, fundamentals and investor tools on this site. Investors Welcome to the WiseTech Global investor centre. Add Files. Sea Containers 18 Upper Ground London, SE1 9GL. The Investor Centre provides a variety of important holding information and communication preferences. Seeing the potential for computers in medicine at a time when the profession was still paper based, he co-founded Pro Medicus in 1981, prior to the release of the inaugural IBM PC. View more Opens in new window Select an Area. The Pro Medicus Limited share ... Another business to soar is the Flight Centre Travel Group Ltd share price, it’s ... Jaz is a keen investor who loves to thoroughly poke holes in an investment idea before it has a chance of making it into her portfolio. Appendix 4D and Financial Statements 1H2020. Pro Medicus is a Melbourne-based software owner and developer, licensing products to large US hospitals and Australian radiology clinics. 2020 Annual Report. Read More The company is well-placed, with no debt, a growing cash balance, high margins and return on equity. Our products provide innovative treatment solutions derived from the regenerative properties of a patient’s own skin. 4Dx is pleased to announce the appointment of Dr. Sam Hupert, co-Founder and CEO of Pro Medicus (ASX: PME) to the 4Dx advisory board. I discovered that the median total compensation for the CEOs of companies like Pro Medicus with market caps between AU$2.6b and AU$8.4b is about AU$2.5m. Pro Medicus Limited shares are up more than 6% after the healthcare company reported its half year result. View more. Through Domain, Allhomes and Commercial Real Estate, we deliver property marketing solutions for residential, new development and commercial properties, plus the latest market intel that attracts qualified buyers, sellers, renters and investors to your listings. Pro Medicus has announced plans to expand into other medical imaging fields, including cardiology and ophthalmology. Add Files. Welcome to Integral Diagnostics investor centre. That's because on our analysis the CEO, Sam Hupert, is paid less than the median for similar sized companies. Investor Presentation 1H2020. Dr. Hupert has made a private investment into 4Dx and agreed to sit on 4Dx’s advisory board, bringing with him more than 37 years of success as a leader in the global healthcare medtech and imaging IT community. This comes despite the company announcing a new contract award with a major university health system in the United States. Pro Medicus is a medical imaging software company, generating sales from its Visage product across North America and Europe as well as Asia-Pacific. Add Files. Computershare Investor Services Pty Limited GPO Box 2975 Melbourne VIC 3001 AUSTRALIA. HIN/SRN . How did this company succeed in a sector where others have failed or are acquired before they can realise their full potential? With Pro Medicus currently trading at 145 times trailings earnings, Alan Kohler catches up with the company's CEO, Dr Sam Hupert to decipher whether the stock is overpriced, what growth is ahead to justify its valuation, and its recent deal with Ludwig-Maximilians University in Germany. Appendix 4E and Financial Statements FY2019. Issuer Name. With our global reach, we see into the world's supply chain at a breadth and depth that allows us to identify and build large, deeper next-generation functionality, global data sets and powerful transactional execution capabilities. Annual & Interim Reports Year. 2019. View our 2019 Annual Report here. About 80% of revenue comes from the North American market, in which Pro Medicus grew revenue by 43% in the December 2019 half-year. 2019 Annual Report 7.1 MB. Find out more at Eureka Report. View single holding by entering all your details. Pro Medicus CEO Dr Sam Hupert is one of the co-founder of the multi-billion dollar business. I have read and agree to the terms & conditions. The product line comprises solutions for RIS (Radiology Information Systems) /Practice Management, Healthcare Imaging, and e-health. Every investor in Pro Medicus Limited (ASX:PME) should be aware of the most powerful shareholder groups. Philip was involved in non–executive roles in both the not-for-profit and corporate sectors. Corporate Governance Responsibilities. Investor information about Volpara Health Technologies (ASX: VHT), developers of digital health services to enable personalised, high quality breast cancer screening based on objective measurements of breast density, compression and radiation dose. 2019 Interim Report 5.5 MB. Investor centre. The business generates revenue on a 'pay-per-click' basis, with guaranteed transaction minimums over contracts of five years or more.